SRR600361
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.326
- KRAS_SIGNALING_DN+0.244
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.229
- APICAL_JUNCTION+0.220
- SPERMATOGENESIS+0.170
- MYOGENESIS+0.162
- PANCREAS_BETA_CELLS+0.123
- HEDGEHOG_SIGNALING+0.117
- APICAL_SURFACE+0.112
- UV_RESPONSE_DN+0.098
Top 10 suppressed
- E2F_TARGETS-0.471
- G2M_CHECKPOINT-0.448
- TNFA_SIGNALING_VIA_NFKB-0.446
- NOTCH_SIGNALING-0.426
- MYC_TARGETS_V1-0.416
- TGF_BETA_SIGNALING-0.383
- UNFOLDED_PROTEIN_RESPONSE-0.338
- DNA_REPAIR-0.298
- IL6_JAK_STAT3_SIGNALING-0.289
- MYC_TARGETS_V2-0.269
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR615838 | GTEX | — | 0.912 |
| 2 | SRR1480059 | GTEX | — | 0.904 |
| 3 | SRR1348339 | GTEX | — | 0.903 |
| 4 | SRR1082262 | GTEX | — | 0.896 |
| 5 | SRR1440058 | GTEX | — | 0.896 |
| 6 | SRR1414897 | GTEX | — | 0.884 |
| 7 | SRR1341763 | GTEX | — | 0.883 |
| 8 | SRR1373858 | GTEX | — | 0.879 |
| 9 | SRR1445347 | GTEX | — | 0.879 |
| 10 | SRR817797 | GTEX | — | 0.877 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.326 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.244 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.229 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.220 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.170 | Inavolisib | — uncovered |
| MYOGENESIS | 0.162 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.123 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.117 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.112 | Temsirolimus | — uncovered |
| UV_RESPONSE_DN | 0.098 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.083 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.057 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.029 | Idelalisib | — uncovered |
| PEROXISOME | 0.020 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.005 | Inavolisib | — uncovered |